Skip to main content

Richard Frothingham

Associate Professor of Medicine
Medicine, Infectious Diseases
DUMC Box 102359, Infectious Disease, Durham, NC 27710
2424 Erwin Rd, Hock Plaza Room 9089, Durham, NC 27710

Overview


Dr. Frothingham is the principal investigator of a research laboratory which studies Mycobacterium tuberculosis, the cause of tuberculosis, and Mycobacterium avium, a closely related bacterium causing serious infections in AIDS patients. We are pursuing two current projects.

The first project aims to develop vaccines against M. avium and M. tuberculosis. We inject mice with candidate plasmid DNA vaccines which produce bacterial proteins in mouse muscle. We use a variety of DNA adjuvants to modify the immune response. We hope to use DNA vaccination to protect against new infections and to modify the course of existing infections. We also hope to identify correlates of vaccine-induced protective immunity.

The second project uses variations in bacterial DNA sequences to identify species and strains. Dr. Frothingham was part of a team of four Duke scientists who used DNA sequence analysis to identify the cause of Whipple's disease. He also identified used DNA sequence to identify a particular group of M. avium strains which cause disseminated infections in AIDS patients. We recently developed a new tuberculosis typing method using variable numbers of tandem DNA repeats. We are applying this new typing method in national and international collaborations.

Dr. Frothingham does not currently conduct clinical trials.

Special areas of expertise include tuberculosis, mycobacteria, strain differentiation, DNA vaccination, and pyrazinamide.

Key words: tuberculosis, mycobacteria, Mycobacterium tuberculosis, Mycobacterium avium, DNA vaccines, tandem repeat DNA, pyrazinamide, mouse

Current Appointments & Affiliations


Associate Professor of Medicine · 2017 - Present Medicine, Infectious Diseases, Medicine
Member of the Duke Human Vaccine Institute · 2005 - Present Duke Human Vaccine Institute, Institutes and Centers

Recent Publications


Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.

Journal Article Vaccine · October 13, 2015 BACKGROUND: A recombinant Mycobacterium bovis BCG (rBCG) vector expressing HIV transgenes is an attractive candidate as a dual vaccine against HIV and TB. However, pre-existing immune responses to mycobacteria may influence immune responses to rBCG. We ana ... Full text Link to item Cite

Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors.

Journal Article Clin Vaccine Immunol · July 2015 The well-established safety profile of the tuberculosis vaccine strain, Mycobacterium bovis bacille Calmette-Guérin (BCG), makes it an attractive vehicle for heterologous expression of antigens from clinically relevant pathogens. However, successful genera ... Full text Link to item Cite

Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques.

Journal Article Clin Vaccine Immunol · October 2014 Live attenuated nonpathogenic Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediates long-lasting immune responses, has been safely administered as a tuberculosis vaccine to billions of humans, and is affordable to produce as a vaccine vector. These c ... Full text Link to item Cite
View All Publications

Recent Grants


EQAPOL - 2016 to 2017 - Option 6 - BASE

ResearchInvestigator · Awarded by National Institutes of Health · 2010 - 2017

EQAPOL Option 5

ResearchInvestigator · Awarded by National Institutes of Health · 2010 - 2017

Animal Models of Infectious Diseases Part A

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2010 - 2017

View All Grants

Education, Training & Certifications


Duke University · 1981 M.D.